Ligand Provides A 5-Year Outlook; Adjusted Diluted EPS Outlook For 2028 Is In The Range Of $10.00-$10.50; Total Core Revenue Could Reach ~$290M By 2028
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals provided a five-year outlook, projecting significant growth. The company anticipates a 16% CAGR in royalties from existing commercial programs and partnerships, potentially increasing to over 20% with future investments. Ligand expects total core revenue to reach approximately $290 million by 2028, with an EBITDA margin exceeding 80%. The adjusted diluted EPS forecast for 2028 is between $10.00 and $10.50.
December 12, 2023 | 5:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals anticipates strong growth over the next five years, with a 16-20%+ CAGR in royalties, projected core revenue of $290M, and an EBITDA margin over 80% by 2028. Adjusted EPS is expected to be $10.00-$10.50.
The positive outlook provided by Ligand Pharmaceuticals is likely to instill confidence in investors, potentially leading to a short-term increase in stock price. The projected growth in royalties, revenue, and EBITDA margin, along with a strong EPS forecast, are all positive indicators that can attract investment and drive up the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100